Tappt App for Hepatitis C
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new app called Tappt, designed to help people with hepatitis C track their medication use. The goal is to determine if the app can improve adherence to treatment plans and aid in successfully clearing the virus. The trial will compare the outcomes of app users with past records of those who did not use it. Individuals with hepatitis C who are beginning specific oral treatments and own a smartphone may be suitable candidates for this study. As an unphased trial, this study allows participants to contribute to innovative research that may enhance treatment adherence for others with hepatitis C.
Will I have to stop taking my current medications?
The trial does not specify whether you need to stop taking your current medications. However, it focuses on starting a new oral medication for hepatitis C, so it's best to discuss your current medications with the study team.
What prior data suggests that the Tappt app is safe for individuals with hepatitis C?
Research has shown that digital tools like the Tappt app are generally easy for people to use. One study on a digital program for treating hepatitis C (HCV) found that it helped people take their medication regularly without causing major side effects. This suggests that using a digital app like Tappt is likely safe for participants.
Other studies on telemedicine for HCV have successfully used similar digital methods. These methods made treatment more accessible and improved patient engagement in their care. This evidence suggests that the Tappt app can safely help manage HCV treatment, assisting users in maintaining their medication regimen while reducing risks.12345Why are researchers excited about this trial?
Researchers are excited about the Tappt App because it offers a new way to enhance treatment adherence for Hepatitis C patients. Unlike traditional treatments that rely solely on patient discipline to follow medication schedules, the Tappt App uses a technology-driven approach by allowing patients to scan tags to track their medication intake. This innovative method not only helps patients stay on track with their medication regimen but also provides real-time data that can potentially improve treatment outcomes and ensure higher rates of sustained virologic response (SVR).
What evidence suggests that the Tappt app is effective for improving medication adherence in hepatitis C patients?
Research has shown that treatments for Hepatitis C, known as direct-acting antivirals, are effective for over 90% of patients, helping most eliminate the virus. One study found that 91% of patients completed their treatment with successful results. In this trial, participants in the Tappt App arm will use the app to ensure timely medication intake, which is crucial for these treatments to be effective. By aiding adherence to medication schedules, Tappt aims to support similar positive outcomes in Hepatitis C treatment.56789
Who Is on the Research Team?
Michelle Martin
Principal Investigator
UIH
Are You a Good Fit for This Trial?
This trial is for adults over 18 with hepatitis C starting oral therapy managed by a clinical pharmacist at UI Health. Participants must understand English, have access to a smartphone (iPhone 7/Android from 2012 or newer) with data/Wi-Fi, and be willing to consent.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants utilize the Tappt app to record adherence to oral medication for hepatitis C virus (HCV) treatment
Follow-up
Participants are monitored for sustained virologic response (SVR) and treatment completion
What Are the Treatments Tested in This Trial?
Interventions
- Tappt
Trial Overview
The study tests the Tappt app's effectiveness in helping patients stick to their hepatitis C medication schedule. It measures if using Tappt is as good as standard care for keeping up with meds, finishing treatment, and clearing the virus.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants will download and utilize the Tappt app to record adherence to oral medication. For the purposes of this study, adherence for participants in the intervention arm will be measured using a modified medication possession ratio (MPR) measure called medication tag scan ratio (MTSR). MTSR is defined as a percentage of the number of times participants scanned their passive tags versus the total of expected tag scans based on that participant's medication regimen and treatment period.
Upon study completion, a retrospective matched control will be established for the intervention group. Historic data for the matched control's adherence, treatment completion, SVR assessment, and SVR rates will be compared to the intervention arm.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Illinois at Chicago
Lead Sponsor
American Society of Health-System Pharmacists
Collaborator
Synchronyx
Collaborator
Published Research Related to This Trial
Citations
Tappt App for Hepatitis C
Research shows that direct-acting antiviral treatments for Hepatitis C, which are similar to Tappt, have high success rates, with more than 90% of patients ...
Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment ...
Of the 203 HCV treatment applications, 87% (n = 176) of patients were approved for treatment, 91% (n = 161) of whom completed treatment. Of the 161 patients who ...
Financial incentives to increase engagement across the ...
We conducted a systematic review to assess evidence regarding the effectiveness of financial incentives to improve engagement and progression through the HCV ...
Design and Baseline Characteristics of the STOP-C Trial
All received 12 weeks of oral direct-acting antiviral therapy. The primary outcome is sustained virologic response 12 weeks after treatment ...
A Mobile Health Intervention to Improve Hepatitis C ...
Four primary outcomes will be examined: undergoing HCV testing, linking to HCV medical care, initiating HCV treatment, and achieving a sustained ...
Peer-assisted telemedicine hepatitis-C treatment for ...
This low-barrier model makes space for PWUD to receive HCV treatment, regardless of drug use.
Integrated Hepatitis C–Opioid Use Disorder Care Through ...
This study discusses whether facilitated telemedicine for hepatitis C treatment increases cure rates compared with standard-of-care referral ...
Lessons Learned from a Mobile Telehealth HCV Testing and ...
In this commentary, we discuss lessons learned delivering telehealth on a mobile unit, important factors for consideration when designing a mobile intervention.
Impact of a digital medicine programme on hepatitis C ...
Aims To conduct a prospective, single‐arm, open‐label study across the United States to assess the impact of DMP on adherence and efficacy in ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.